Phase I clinical trials of a new HIV vaccine developed by researchers at the University of Regensburg in Germany will begin in June in Switzerland and the United Kingdom, Reuters Health reports. The vaccine will be tested in about 160 HIV-negative volunteers to determine its safety profile. Efficacy tests are scheduled for 2005. The vaccine, called DNA-C, uses a two-injection process to produce a protective immune system response by using key HIV genes to prime the immune system to recognize and attack the HIV virus when it tries to enter the body. The initial stage of the clinical trial will give each volunteer only one of the two injections; combination injections will be given to trial participants after the individual safety profiles are established.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes
These are some of his worst comments about LGBTQ+ people made by Charlie Kirk.